Cassava Sciences Reports Positive Phase 2a Clinical Results in Alzheimer’s Patients
Cassava Sciences, Inc. (SAVA)
Last cassava sciences, inc. earnings: 8/12 08:30 am
Check Earnings Report
Company Research
Source: GlobeNewswire
Lead drug candidate, PTI-125, significantly decreased key biomarkers of neuroinflammation and neurodegeneration in all study patients (p Clinical data support initiation of a Phase 2b study in Alzheimer’s in Q3 2019 AUSTIN, Texas, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biopharmaceutical company, today reported positive top-line clinical results of its lead drug candidate for Alzheimer’s disease, PTI-125. The Alzheimer’s brain is characterized by a misfolded protein called Filamin A (FLNA); PTI-125 binds to FLNA and restores its normal shape and function. In a Phase 2a study funded by the National Institutes of Health (NIH), treatment with PTI-125 for 28 days significantly reduced biomarkers of Alzheimer’s disease pathology, neuroinflammation and neurodegeneration in patients. “Based on these encouraging biomarker results, this new treatment could be an important part of the research dialogue in Alzheimer’s disease,” said Dr. Jeffrey Cummings,
Show less
Read more
Impact Snapshot
Event Time:
SAVA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SAVA alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SAVA alerts
High impacting Cassava Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
SAVA
News
- Shareholders that lost money on Cassava Sciences, Inc. (SAVA) should contact Levi & Korsinsky about pending Class Action - SAVAAccesswire
- ROSEN, LEADING TRIAL ATTORNEYS, Encourages Cassava Sciences, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SAVAGlobeNewswire
- Class Action Filed Against Cassava Sciences, Inc. (SAVA) - February 10, 2025 Deadline to Join – Contact Levi & KorsinskyAccesswire
- SAVA Class Action Alert: Shareholder Rights Law Firm Robbins LLP Reminds Investors of the Lead Plaintiff Deadline in the Class Action Against Cassava Sciences, Inc. Accesswire
- Lost Money on Cassava Sciences, Inc. (SAVA)? Join Class Action Suit Seeking Recovery - Contact Levi & KorsinskyAccesswire
SAVA
Earnings
- 11/7/24 - Beat
SAVA
Sec Filings
- 12/3/24 - Form 4
- 12/3/24 - Form 4
- 12/2/24 - Form 144
- SAVA's page on the SEC website